MX381995B - Métodos para la producción de polipéptidos procesados proteolíticamente. - Google Patents

Métodos para la producción de polipéptidos procesados proteolíticamente.

Info

Publication number
MX381995B
MX381995B MX2019000098A MX2019000098A MX381995B MX 381995 B MX381995 B MX 381995B MX 2019000098 A MX2019000098 A MX 2019000098A MX 2019000098 A MX2019000098 A MX 2019000098A MX 381995 B MX381995 B MX 381995B
Authority
MX
Mexico
Prior art keywords
methods
production
proteolytically processed
processed polypeptides
polypeptides
Prior art date
Application number
MX2019000098A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Rummel
Original Assignee
Ipsen Bioinnovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioinnovation Ltd filed Critical Ipsen Bioinnovation Ltd
Publication of MX381995B publication Critical patent/MX381995B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
MX2019000098A 2012-11-21 2012-11-21 Métodos para la producción de polipéptidos procesados proteolíticamente. MX381995B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/073283 WO2014079495A1 (en) 2012-11-21 2012-11-21 Methods for the manufacture of proteolytically processed polypeptides

Publications (1)

Publication Number Publication Date
MX381995B true MX381995B (es) 2025-03-13

Family

ID=47216287

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019000098A MX381995B (es) 2012-11-21 2012-11-21 Métodos para la producción de polipéptidos procesados proteolíticamente.
MX2015002390A MX363788B (es) 2012-11-21 2012-11-21 Métodos para la producción de polipéptidos procesados proteolíticamente.
MX2015006324A MX2015006324A (es) 2012-11-21 2013-11-21 Metodos para la fabricacion de polipeptidos proteoliticamente procesados.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2015002390A MX363788B (es) 2012-11-21 2012-11-21 Métodos para la producción de polipéptidos procesados proteolíticamente.
MX2015006324A MX2015006324A (es) 2012-11-21 2013-11-21 Metodos para la fabricacion de polipeptidos proteoliticamente procesados.

Country Status (14)

Country Link
US (4) US10087432B2 (enExample)
JP (3) JP6156954B2 (enExample)
KR (4) KR102083371B1 (enExample)
CN (5) CN120118892A (enExample)
AR (3) AR093578A1 (enExample)
AU (2) AU2012395188B2 (enExample)
BR (2) BR112015003591B1 (enExample)
CA (2) CA3062150C (enExample)
IN (1) IN2015DN01449A (enExample)
MX (3) MX381995B (enExample)
RU (2) RU2673910C2 (enExample)
TW (5) TW201839133A (enExample)
UA (2) UA111795C2 (enExample)
WO (2) WO2014079495A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792344B2 (en) * 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
MX381995B (es) * 2012-11-21 2025-03-13 Ipsen Bioinnovation Ltd Métodos para la producción de polipéptidos procesados proteolíticamente.
US10408837B2 (en) * 2013-12-09 2019-09-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide substrates recognizable by type E botulinum neurotoxin
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
EP3156412B1 (en) * 2014-05-29 2020-01-08 Procell Therapeutics Inc. Novel cell penetrating peptide, conjugate thereof with botulinum toxin, and use thereof
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények
ES3004533T3 (en) * 2017-10-13 2025-03-12 Wisconsin Alumni Res Found Botulinum neurotoxin a subtype 6 and pharmacological methods of use
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
KR102246906B1 (ko) * 2019-04-29 2021-04-30 주식회사 바이오셀트란 피부 또는 세포 투과능이 우수한 피부주름 방지 또는 개선용 화장료 조성물
KR20220154738A (ko) 2020-03-16 2022-11-22 입센 바이오팜 리미티드 사지 경직을 치료하기 위한 변형된 보툴리눔 신경독소
GB202003813D0 (en) 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
KR20240067070A (ko) 2021-09-16 2024-05-16 입센 바이오팜 리미티드 경부 이상긴장증의 치료에 사용하기 위한 변형된 bont/a
JP2024534541A (ja) 2021-09-23 2024-09-20 イプセン バイオファーム リミテッド 被験体の眼瞼筋を冒す障害の治療における使用のための改変ＢｏＮＴ／Ａ
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
KR20240116485A (ko) 2021-11-22 2024-07-29 입센 바이오팜 리미티드 통증의 치료
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202206361D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202206362D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202307439D0 (en) 2023-05-18 2023-07-05 Ipsen Biopharm Ltd Treatment of a headache disorder with botylinum neurotoxin a
WO2025093844A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
WO2025093845A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
GB202320108D0 (en) 2023-12-28 2024-02-14 Ipsen Biopharm Ltd Biosensor
DE102025101336A1 (de) * 2024-01-19 2025-07-24 Abbvie Inc. Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US8153397B2 (en) * 1993-09-21 2012-04-10 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
WO1996005222A1 (en) * 1994-08-08 1996-02-22 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8012491B2 (en) * 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
DE19856897A1 (de) 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
US7740868B2 (en) * 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
CA2380457A1 (en) * 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US7402556B2 (en) 2000-08-24 2008-07-22 Medarex, Inc. Prodrugs activated by plasmin and their use in cancer chemotherapy
TW526437B (en) * 2001-08-08 2003-04-01 Macronix Int Co Ltd Photolithography rework analysis method and system
AU2003237346A1 (en) * 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20040018589A1 (en) * 2002-07-25 2004-01-29 Jun Zhong Method for producing biologically active botulinum neurotoxins through recombinant DNA technique
CA2492883C (en) 2002-08-01 2012-10-02 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2004031355A2 (en) * 2002-10-01 2004-04-15 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
WO2005030119A2 (en) 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US20080171347A1 (en) 2003-04-11 2008-07-17 Atassi M Zouhair Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
US20050169942A1 (en) * 2003-10-07 2005-08-04 Allergan, Inc. Novel DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain for production of therapeutics
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
EP1773874B1 (en) * 2004-08-04 2012-10-24 Allergan, Inc. Optimizing expression of active botulinum toxin type a
WO2006026780A1 (en) * 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US7659092B2 (en) * 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
US8021859B2 (en) * 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
CA2601592A1 (en) * 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US7465457B2 (en) * 2005-04-14 2008-12-16 Wisconsin Alumni Research Foundation Method for preparing botulinum neurotoxin type A light chain
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
DK1926744T4 (en) * 2005-09-19 2019-01-28 Allergan Inc CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES
US9072735B2 (en) 2005-10-03 2015-07-07 Yong Qian Proteinases destroy cancer tumor's solid structure and kill cancer cells locally
US7464917B2 (en) * 2005-10-07 2008-12-16 Appiled Materials, Inc. Ampoule splash guard apparatus
DE102005051789B4 (de) * 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
WO2008008803A2 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
KR100677871B1 (ko) * 2006-09-11 2007-02-02 주식회사 메가젠 골충진재 성형 장치 및 골충진재 성형 방법
EP2167119B1 (en) * 2007-06-14 2016-08-24 The Secretary of State for Health Chemically modified peptides with improved immunogenicity
EP2178905B1 (en) * 2007-07-26 2013-11-06 Allergan, Inc. Methods of activiting clostridial toxins
EP2023327A1 (en) * 2007-07-27 2009-02-11 Foxboro Eckardt Gmbh Operation voltage controller and method for controlling an operation voltage controller
US20090104234A1 (en) * 2007-10-23 2009-04-23 Allergan, Inc. Methods of treating chronic neurogenic inflammation using modified clostridial toxins
RU2010120016A (ru) * 2007-10-23 2011-11-27 Аллерган, Инк. (Us) Способы лечения хронического нейрогенного воспаления с применением модифицированных клостридиальных токсинов
KR101609894B1 (ko) * 2008-03-14 2016-04-08 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US8492109B2 (en) * 2009-01-20 2013-07-23 Trustees Of Tufts College Methods for the delivery of toxins or enzymatically active portions thereof
EP2398824B1 (en) * 2009-02-19 2018-12-26 Merz Pharma GmbH & Co. KGaA Means and methods for manufacturing highly pure neurotoxin
NZ594702A (en) * 2009-03-13 2013-05-31 Allergan Inc The SiMA cell line used for immuno-based or gene expression Botulinum Serotype A activity assays
US8663942B2 (en) * 2009-04-27 2014-03-04 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303757A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
AU2010267963B2 (en) * 2009-07-02 2015-09-24 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
US10246492B2 (en) * 2009-10-16 2019-04-02 Biomadison, Inc. Botulinum assay with synaptobrevin substrate moiety
WO2011047265A1 (en) * 2009-10-16 2011-04-21 Biosentinel, Inc. Resonance energy transfer assay with synaptobrevin substrate moiety
CA2784666A1 (en) 2009-12-16 2011-11-17 Allergan, Inc. Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
US20130245227A1 (en) * 2010-01-15 2013-09-19 Allergan, Inc. Methods of activating clostridial toxins
CA2788074C (en) * 2010-01-25 2016-07-12 Allergan, Inc. Methods of intracellular conversion of single-chain proteins into their di-chain form
AT511002A1 (de) * 2011-02-08 2012-08-15 Univ Innsbruck Verfahren zur verformung von cellulosecarbamat und produkte, die nach diesem verfahren hergestellt werden
US20120207734A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
WO2012112432A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases
GB201108108D0 (en) * 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
EP4375371A3 (en) * 2011-05-19 2024-07-31 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
CA2855173A1 (en) * 2011-11-09 2013-05-16 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
WO2013131991A1 (en) * 2012-03-07 2013-09-12 Merz Pharma Gmbh & Co. Kgaa Means and methods for determining neurotoxin activity based on a modified luciferase
KR101729710B1 (ko) * 2012-04-09 2017-04-24 서울대학교산학협력단 물에 안정하게 분산되는 멜라닌 나노입자를 포함하는 핵자기 공명 영상 조영제
ES2847241T3 (es) * 2012-05-30 2021-08-02 Harvard College Neurotoxina botulínica genéticamente modificada
JP2015527067A (ja) * 2012-08-20 2015-09-17 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト アウフ アクティーン Ｎ末端リシンを包有する組換タンパク質を製造する新規の方法
MX381995B (es) * 2012-11-21 2025-03-13 Ipsen Bioinnovation Ltd Métodos para la producción de polipéptidos procesados proteolíticamente.
EP2922822B1 (en) * 2012-11-22 2016-12-28 Sanofi Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of same
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
EP3230457B1 (en) * 2014-12-09 2021-06-30 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
US9913875B2 (en) * 2015-03-16 2018-03-13 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
GB201505306D0 (en) * 2015-03-27 2015-05-13 Ipsen Biopharm Ltd Chimeric polypeptides
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EA201892643A1 (ru) * 2016-05-16 2019-06-28 Президент Энд Феллоуз Оф Гарвард Колледж Способ очистки и активации ботулинического нейротоксина
PL3481852T3 (pl) * 2016-07-08 2023-07-24 Children's Medical Center Corporation Nowa neurotoksyna botulinowa i jej pochodne

Also Published As

Publication number Publication date
MX2015002390A (es) 2015-08-05
KR102083371B1 (ko) 2020-03-04
TW201839134A (zh) 2018-11-01
BR112015003591A8 (pt) 2017-08-22
BR112015003591B1 (pt) 2022-02-01
JP2019030333A (ja) 2019-02-28
KR20170059007A (ko) 2017-05-29
BR112015003591A2 (enExample) 2015-02-20
AU2012395188A1 (en) 2015-03-05
CA2880897C (en) 2020-01-14
KR20180077343A (ko) 2018-07-06
US20200339971A1 (en) 2020-10-29
RU2673910C2 (ru) 2018-12-03
RU2015124069A (ru) 2017-01-10
TW201439322A (zh) 2014-10-16
CA3062150C (en) 2021-12-21
US10808236B2 (en) 2020-10-20
BR112015010550A8 (pt) 2018-01-02
MX363788B (es) 2019-04-03
KR102083373B1 (ko) 2020-03-03
KR20150041790A (ko) 2015-04-17
AU2012395188B2 (en) 2017-06-01
AR118019A2 (es) 2021-09-08
CN104797595A (zh) 2015-07-22
IN2015DN01449A (enExample) 2015-07-03
CN104870468B (zh) 2020-11-10
UA117231C2 (uk) 2018-07-10
HK1210191A1 (en) 2016-04-15
US10087432B2 (en) 2018-10-02
TW201839133A (zh) 2018-11-01
TWI709649B (zh) 2020-11-11
CN120118892A (zh) 2025-06-10
US20150225709A1 (en) 2015-08-13
AR093578A1 (es) 2015-06-10
US20230015772A1 (en) 2023-01-19
US11441141B2 (en) 2022-09-13
CN104870468A (zh) 2015-08-26
TW201839135A (zh) 2018-11-01
CN111454931A (zh) 2020-07-28
MX2015006324A (es) 2015-09-07
AU2012395188A2 (en) 2015-04-09
JP6156954B2 (ja) 2017-07-05
CA2880897A1 (en) 2014-05-30
RU2015107240A (ru) 2016-09-27
BR112015010550A2 (pt) 2017-08-22
CN104797595B (zh) 2021-01-29
TW201839132A (zh) 2018-11-01
JP2015536644A (ja) 2015-12-24
JP2015536654A (ja) 2015-12-24
WO2014080206A1 (en) 2014-05-30
US20190100739A1 (en) 2019-04-04
KR20150085844A (ko) 2015-07-24
WO2014079495A1 (en) 2014-05-30
AR127620A2 (es) 2024-02-14
AU2017221793A1 (en) 2017-09-21
AU2017221793B2 (en) 2019-05-16
UA111795C2 (uk) 2016-06-10
CA3062150A1 (en) 2014-05-30
TWI713862B (zh) 2020-12-21
CN112048009A (zh) 2020-12-08

Similar Documents

Publication Publication Date Title
MX381995B (es) Métodos para la producción de polipéptidos procesados proteolíticamente.
CL2014003568A1 (es) Células transformadas para producir iduronato-2-sulfatasa (i2s) recombinante; método de producción de i2s recombinante; y proteína i2s recombinante.
MX2017006866A (es) Pares de unión para producción de péptidos.
MX2016000306A (es) Celulas de hongos filamentosos deficientes en multiples proteasas y métodos de uso de las mismas.
EP4375371A3 (en) Methods for the manufacture of proteolytically processed polypeptides
EA201492221A1 (ru) Полипептиды, имеющие активность трансгалактозилирования
UY34254A (es) Proteínas y péptidos modificados.
HRP20190484T1 (hr) Pripravci stanične kulture i postupci proizvodnje polipeptida
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
ECSP15043422A (es) Un procedimiento para aumentar la formacion de acido piroglutamico de una proteina
BR112013028251A2 (pt) polipeptídeo
EP3546481C0 (en) ANTI-INTERLEUKIN 22 ANTIBODIES (IL-22) AND THEIR USES
MX390701B (es) Manufactura de proteína.
IN2014DN10710A (enExample)
HK1215073A1 (zh) 用作評估寶石形狀的方法
FI20115328A7 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
EP2956086A4 (en) ELECTROCHEMICAL PROCESSING OF MATERIALS, METHOD AND MANUFACTURE
WO2014182684A3 (en) Methods and compositions related to large scale production of proteins
EP2984935A4 (en) PROTEIN COMPOSITION AND METHOD FOR MANUFACTURING THE SAME
MX2015007712A (es) Polipeptidos del factor vii de accion corta.
UY34150A (es) Cristal de compuesto heterociclico fusionado
MY184085A (en) Method of protein manufacture
IN2013CH02496A (enExample)
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
IN2014DN11218A (enExample)